Diameter of tumor blood vessels is a good parameter to estimate HIF-1-active regions in solid tumors

Biochemical and Biophysical Research Communications

Volumn 373, Issue 4, 2008, Pages 533-538

  Harada, Hiroshi ^a,b   Xie, Xuejun ^a,c   Itasaka, Satoshi ^a   Zeng, Lihua ^a,c   Zhu, Yuxi ^a   Morinibu, Akiyo ^a   Shinomiya, Kazumi ^a   Hiraoka, Masahiro ^a,b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Hypoxia; Hypoxia inducible factor 1 (HIF 1); Hypoxia response element (HRE); Optical imaging; Tumor microenvironment; Vascular endothelial cell growth factor (VEGF)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL DIAMETER; HUMAN; HUMAN CELL; IMAGING; MOLECULAR DYNAMICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LUMINESCENT PROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50949104613     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.06.062     Document Type: Article

References (16)

1. In: Brown J.M., Metha M.P., and Nieder C. (Eds). Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy (2006), Springer
2. Verellen D., Ridder M.D., Linthout N., Tournel K., Soete G., and Storme G. Innovations in image-guided radiotherapy. Nat. Rev. Cancer 7 (2007) 949-960
3. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
4. Dewhirst M.W., Cao Y., and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8 (2008) 425-437
5. Hirota K., and Semenza G.L. Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem. Biophys. Res. Commun. 338 (2005) 610-616
6. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
7. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
8. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
9. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19 (2000) 59-65
10. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., Seetharam S., Koons A., Hari D.M., Kufe D.W., and Weichselbaum R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
11. Greco O., Patterson A.V., and Dachs G.U. Can gene therapy overcome the problem of hypoxia in radiotherapy?. J. Radiat. Res. (Tokyo) 41 (2000) 201-212
12. Shibata T., Akiyama N., Noda M., Sasai K., and Hiraoka M. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 913-916
13. Shibata T., Giaccia A.J., and Brown J.M. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene. Ther. 7 (2000) 493-498
14. Liu J., Qu R., Ogura M., Shibata T., Harada H., and Hiraoka M. Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J. Radiat. Res. (Tokyo) 46 (2005) 93-102
15. Harada H., Kizaka-Kondoh S., and Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol. Imaging 4 (2005) 182-193
16. Harada H., Kizaka-Kondoh S., Itasaka S., Shibuya K., Morinibu A., Shinomiya K., and Hiraoka M. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem. Biophys. Res. Commun. 360 (2007) 791-796